Apart from the phase I/II study, the company expects to begin three additional studies on KTE-C19 for indications like mantle cell lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia before 2015 end. and potentially launch the candidate in 2017. Positive results would allow the company to file for approval in the U.S. Kite Pharma expects pivotal data from the DLBCL study on KTE-C19 in 2016. Based on the progress of the KTE-C19 development program, Kite Pharma has agreed to make certain milestone payments and provide financial support to LLS. In addition, LLS will start a broad scope educational program focusing on CAR T-cell therapy for the treatment of patients with blood cancer as well as help carry out clinical trial enrollment. The study is being conducted to evaluate the safety and efficacy of KTE-C19 in patients suffering from refractory diffuse large B cell lymphoma (DLBCL) including two rare lymphomas – primary mediastinal B cell lymphoma and transformed follicular lymphoma. Under the deal, LLS will provide up to $2.5 million through its Therapy Acceleration Program to support Kite Pharma's ongoing phase I/II study on KTE-C19. KTE-C19 is being developed as an experimental treatment in which a patient's T cells are genetically modified to express a chimeric antigen receptor (CAR) designed to target CD19. Kite Pharma’s shares were up 4.2% following the announcement. KITE has struck yet another deal – the company entered into a collaboration agreement with The Leukemia & Lymphoma Society (LLS) for the development of its lead pipeline candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |